Latest Janssen Pharmaceuticals Inc. Stories
PHILADELPHIA, March 20, 2015 /PRNewswire/ -- A Philadelphia jury today affirmed by a 10-2 vote that Janssen Pharmaceuticals, a division of Johnson & Johnson, failed to warn of the risk to
Investigational Anti-thrombin Antibody Ichorcumab Strengthens Cardiovascular Disease Portfolio RARITAN, N.J., March 19, 2015 /PRNewswire/ -- Janssen Pharmaceuticals, Inc.
NEWARK, Calif., March 17, 2015 /PRNewswire/ -- Depomed, Inc.
Trial in Philadelphia involves allegations that Janssen Pharmaceuticals and parent company, Johnson & Johnson, failed to warn about the risks of male breast growth, a condition known as gynecomastia,
Johnson & Johnson's bid for a mistrial in a Risperdal case was dismissed by a Pennsylvania state judge, who ruled that the plaintiffs are allowed to bring a new expert to trial after J&J
Xarelto’s low price translates into the lowest out-of-pocket costs to members, according to analysis conducted by the editors of Atlantic Information Services’s new online resource Rx Benefit
TITUSVILLE, N.J., Jan. 15, 2015 /PRNewswire/ -- Janssen Pharmaceuticals, Inc. (JPI) today announced it has entered into a definitive agreement with Depomed, Inc. to divest its U.S.
Findings Add to Rigorous Post-Marketing Safety Program for XARELTO® in Routine Clinical Practice RARITAN, N.J., Jan.
Multidistrict Litigation For Xarelto Bleeding Lawsuits That Allege Patients Experienced Uncontrollable Bleeding And Other Complications After Taking The Prescription Blood Thinner Has Been Established
A Request To Centralize Xarelto Lawsuits Alleging Xarelto Users Experience Uncontrolled Bleeding Due To Taking The Blood Thinner Is Under Consideration By the U.S.
- An aromatic woolly plant (Origanum dictamnus) native to Crete, formerly believed to have magical powers.